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Abstract
Background: Vaccination of neonates is generally difficult due to the immaturity of the immune
system and consequent higher susceptibility to tolerance induction. Genetic immunization has been
described as an alternative to trigger a stronger immune response in neonates, including significant
Th1 polarization. In this investigation we analysed the potential use of a genetic vaccine containing
the heat shock protein (hsp65) from Mycobacterium leprae (pVAXhsp65) against tuberculosis (TB)
in neonate mice. Aspects as antigen production, genomic integration and immunogenicity were
evaluated.
Methods: Hsp65 message and genomic integration were evaluated by RT-PCR and Southern blot,
respectively. Immunogenicity of pVAXhsp65 alone or combined with BCG was analysed by specific
induction of antibodies and cytokines, both quantified by ELISA.
Results: This DNA vaccine was transcribed by muscular cells of neonate mice without integration
into the cellular genome. Even though this vaccine was not strongly immunogenic when entirely
administered (three doses) during early animal's life, it was not tolerogenic. In addition, pVAXhsp65
and BCG were equally able to prime newborn mice for a strong and mixed immune response (Th1
+ Th2) to pVAXhsp65 boosters administered later, at the adult life.
Conclusion: These results suggest that pVAXhsp65 can be safely used as a priming stimulus in
neonate animals in prime-boost similar strategies to control TB. However, priming with BCG or
pVAXhsp65, directed the ensuing immune response triggered by an heterologous or homologous
booster, to a mixed Th1/Th2 pattern of response. Measures as introduction of IL-12 or GM-CSF
genes in the vaccine construct or even IL-4 neutralization, are probably required to increase the
priming towards Th1 polarization to ensure control of tuberculosis infection.
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1. Background
Tuberculosis (TB) is a disease caused by Mycobacterium
tuberculosis (M. tuberculosis) which affects mainly the
lungs. It is a major public-health problem, with around 9
million new cases and 2 million deaths estimated to occur
each year [1].
The attenuated BCG strain of Mycobacterium bovis has been
extensively used as a vaccine against TB for the past several
decades. The vaccine has many virtues, including the fact
that it can be safely given to young children and is inex-
pensive to be produced. However, in spite of its wide use,
a large number of well documented trials have shown that
the protective efficacy of BCG may vary greatly, from 0 to
80% [2]. This highly variable and poorly protective effi-
cacy in certain countries has been attributed to the various
BCG strains used as vaccines, environmental factors and
host genetic characteristics [3,4]. Although the overall effi-
cacy is low, one important observation that is shared by
most studies, is that BCG vaccine protects against dissem-
inated disease in newborns and children. In addition, this
immunity wanes with age, resulting in insufficient protec-
tion against adult pulmonary TB [5,6]. Besides protection
against more severe forms of TB in young children, recent
reports have strongly reinforced the role of bacillus Cal-
mette-Guérin as an immunomodulator for prevention
and treatment of allergy, asthma and autoimmune dis-
eases [7,8].
In this context, there is a great interest in the development
of new vaccines against TB. A number of alternative living
and non-living putative TB vaccines are being studied and
discussed by many authors [9-11]. DNA vaccines have
been successful in several experimental infection models
and some reports provide evidence of their feasibility for
TB control. DNA constructs encoding mycobacterial anti-
gens as 65-kDa heat shock protein (hsp65), Ag85A, Ag85B
and ESAT-6 induced significant protective immunity [12-
14]. Additionally, attempts to improve BCG by adminis-
tering lower doses, oral delivery and prime-boost proto-
cols are being explored [15,16]. An heterologous prime-
boost regimen, which boosts or augments BCG or rBCG,
is being considered the most realistic strategy for future TB
control through immunization [6].
As a new TB vaccine will be administered to human
neonates, it must be realized that newborns and young
infants from numerous animal species show limitations
in generating protective immune responses. Neonatal
murine immunization models using conventional vac-
cine antigens (measles, tetanus toxoid) in BALB/c mice
gave responses similar to those found early in human
infants. Early life B cell responses generally resulted in a
slower and weaker increase of vaccine antibodies com-
pared with adult mice. Furthermore, analyses of T cell
responses to these conventional vaccines indicated that
early life T cell differentiation was preferentially polarized
towards a Th2 pattern [17]. As a consequence of this Th2
bias, there is a deficient production of IFN-γ, TNF-α and
CTL responses, considered essential for protection against
many intracellular pathogens.
In this investigation we analysed the potential use of a
genetic vaccine (pVAXhsp65) against TB in neonate mice.
Aspects as presence of hsp65 message in different tissues,
genome integration and immunogenicity in homologous
and heterologous prime-boost strategies were evaluated.
2. Materials and methods
2.1 Mice
BALB/c mice were bred in the Animal Facility of São Paulo
State University (UNESP) at the Biosciences Institute and
used at 5 (neonates), 12, 19 and 30-day-old. Breeding
cages were checked daily for new births and the day of
birth was recorded as the day the litter was found. Pups
were kept with the mothers until they were weaned at 21-
day-old. The animal protocols used in this work were
approved by the local ethical committee that follows the
guidelines adopted by the Brazilian College of Animal
Experimentation (COBEA).
2.2 Plasmid DNA construction and purification
The vaccine pVAX-hsp65 was derived from the pVAX vec-
tor that use the CMV intron (Invitrogen®, Carlsbad, CA,
USA), previously digested with BamH I and Not I (Gibco
BRL, Gaithersburg, MD, USA) to insert a 3.3 kb fragment
corresponding to the M. leprae hsp65 gene. The empty
pVAX vector was used as a control. DH5α E. coli trans-
formed with plasmid pVAX or the plasmid carrying the
hsp65 gene (pVAX-hsp65) were cultured in LB liquid
medium (Gibco BRL, Gaithersburg, MD, USA) containing
kanamicin (50 μg/ml). The plasmids were purified using
the Concert High Purity Maxiprep System (Gibco BRL,
Gaithersburg, MD, USA). Plasmid concentrations were
determined by spectrophotometry at λ = 260 and 280 nm
by using the Gene Quant II apparatus (Pharmacia Biotech,
Buckinghamshire, UK).
2.3 Vaccines and immunization procedures
In addition to the genetic vaccine (pVAXhsp65) described
above, we also used BCG Moreau strain. Young mice
including newborns were immunized with 50 μg of
pVAXhsp65 (20 μl) in the quadriceps muscle, whereas
adults were immunized with 100 μg of pVAXhsp65 (100
μl). For adults, but not young mice, 10% of saccharose
was added. Corresponding control groups received saline
or pVAX in the same conditions. In the prime-boost type
of experiments, mice received one dose of pAXhsp65 (50
μg) or BCG (105CFU) at 5-day-old and then, at the adult
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life, were boostered with two pVAXhsp65 doses (100 μg
each) administered 30 and 45 days after, respectively.
2.4 Isolation of RNA and detection of hsp65 mRNA by RT-
PCR
At various periods of time (48 and 72 hours and 7 days)
after the administration of pVAXhsp65, samples from
muscle, draining lymph nodes, spleen, thymus, liver, kid-
ney, lung and heart were obtained. The samples were
treated with Trizol reagent (Invitrogen, Carlsbad, CA,
USA) and total RNA was isolated according to the manu-
facturer protocol. Subsequently, RNA was extracted with
chloroform and precipitated with isopropyl alcohol. The
total extracted RNA was dissolved in nuclease-free water
(Invitrogen). Total cellular RNA (10 ug) was reversed tran-
scribed using oligo (dT) primers and reverse transcriptase
(Invitrogen) following manufacturer instructions. The
contaminating plasmid DNA was previously removed by
treatment with DNAse I, amplification-grade (Invitro-
gen). The cDNA (2 ug) was amplified for 35 cycles at 94°C
for 30 seconds, 60°C for 45 seconds and 72°C for 1.5
minutes, using the primer pair 5'-ACC AAC GAT
GGCGTG TCC AT-3' and 5'-TAG AAG GCA CAG TCG
AGG-3', resulting in a 400-bp cDNA encoding hsp65, or
the primer pair 5'-GTG GGC CGC TCT AGG CAC CAA-3'
and 5'-CTC TTT GAT GTC ACG CAC GAT TTC-3', resulting
in a 450-bp cDNA encoding β-actin.
2.5 Quantification of anti-hsp65 antibodies
Serum samples were collected by retro-orbital bleeding
two weeks after the last DNA dose and anti-hsp65 specific
antibody levels were evaluated by enzyme-linked immu-
nosorbent assay (ELISA). Maxisorp plates (Nunc) were
coated with 0,1 ml of purified recombinant hsp65 (5 μg/
ml) in coating solution (14.3 mM Na2CO3, 10.3 mM
NaHCO3, pH 9.6), incubated at 4°C overnight and then
blocked with 10% fetal calf serum (FCS) in PBS for 60
minutes at 37°C. Serum samples diluted 1:25 were tested.
After incubation for 2 hours at 37°C, anti-mouse IgG1
and IgG2a biotinylated conjugates (A85-1 and R19-15,
respectively, from PharMingen), were added for detection
of specific isotype antibodies. After washing, plates were
incubated at room temperature for 30 minutes with
StreptAB kit (Dako, Carpinteria, CA, USA) and then
revealed by adding H2O2 + OPD. Color development was
stopped with H2SO4 and optical density was measured at
492 nm.
2.6 Evaluation of cytokine production
Two weeks after the last DNA dose the animals were sacri-
ficed and splenic cells were collected and adjusted to 5 ×
106 cells/ml in RPMI 1640 medium, supplemented with
5% FCS, 20 mM glutamine and 40 IU/l of gentamicin. The
cells were cultured in 48-well flat-bottomed culture plates
(Nunc, Life Tech. Inc., Maryland, MA, US) in the presence
of 40 μg/ml of Concanavalin A (ConA). Cytokine levels in
culture supernatants were evaluated 48 hours later by
ELISA. Cytokines were measured following manufacturer
instructions (PharMingen). Purified monoclonal antibod-
ies anti-IFN-γ (R4-6A2), IL-4 (11B11) and IL-5 (TRKF5)
were used at 1 μg/ml as capture antibodies and the follow-
ing biotinylated antibodies were used for detection: anti-
IFN-γ (XMG1.2); IL-4 (BVD6) and IL-5 (TRFK4) at 0,5 μg/
ml.
2.7 Statistical analysis
Results are expressed as the mean +/- SEM for each varia-
ble. Statistical analysis was performed using Minitab Ver-
sion 1996 (Minitab Inc, State College, PA, USA). One-way
ANOVA and the Fisher test were used to compare cytokine
and antibody levels. Values of p < 0,05 were considered
statistically significant.
3. Results
3.1 pVAXhsp65 is transcribed in neonate mice immunized 
by intramuscular route
The presence of mRNA for hsp65 was evaluated by RT-
PCR in various tissues at different time points (48 and 72
hours and 7 days) after intramuscular pVAXhsp65 immu-
nization. Fourty-eight hours after immunization, hsp65
transcripts were found in the quadriceps muscle (vaccina-
tion site) but not in any of the other tissues examined as
thymus, spleen, popliteal lymph nodes, liver, lung, heart
and kidney. On days 3 and 7, hsp65 message was still
present in the muscle but did not appear in any of the
other organs. Hsp65 message also appeared in the liver of
one animal (from three tested) at day 7. As expected,
hsp65 transcripts were not detected in tissues from ani-
mals injected with the empty plasmid DNA vector (data
not shown). Also, message for β-actin was detected in all
evaluated samples demonstrating the suitability of RNA
samples for this analysis. The results observed at 48 hours
and 7 days are shown in Figure 1a for lymphoid organs
and 1b for the other organs.
3.2 pVAXhsp65 has immunomodulatory properties in 
young mice
Young mice received three pVAXhsp65 intramuscular
doses delivered at 5, 12 and 19 days of age. Fifteen days
after the last dose they were sacrificed and Th1/Th2 profile
were tested by both, splenic cytokine production in
response to ConA stimulation and anti-hsp65 IgG1 and
IgG2a serum levels. The most prominent alteration was a
significantly higher production of Th2 cytokines (IL-4 and
IL-5, shown in Figures 2b and 2c, respectively) in mice
that received pVAXhsp65 in comparison to the control
ones (not injected or injected with the empty vector). A
discrete and variable increase (with no statistical signifi-
cance) in the production of both isotypes, IgG1 and IgG2a
anti-hsp65, was detected and can be observed at Figure
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2d. pVAXhsp65 did not affect IFN-γ production in a signif-
icant way (Fig. 2a).
3.3 pVAXhsp65 is not tolerogenic for young mice
To evaluate the tolerogenicity of pVAXhsp65 for young
BALB/c mice, animals received a first DNA dose at distinct
ages (5, 12, 19 or 30-day-old) and were then challenged,
three weeks later, at the adult life, with another DNA dose.
Fifteen days after last DNA dose, the serum levels of IgG1
and IgG2a anti-hsp65 antibodies were determined. The
results shown in Figure 3a demonstrated that this vaccine
was not tolerogenic because high specific antibody levels
were detected after the dose administered at the adult
stage. A clear effect of the age on the preferential priming
for IgG2a was observed; the earlier the vaccine was
injected, the higher was the specific IgG2a level (Fig. 3a).
IgG2a anti-hsp65 antibodies were significantly higher in
mice whose priming occurred at 5-day-old, in comparison
to 19 or 30-day-old. Specific IgG1 levels were not affected
by the age of the animal during priming. Interestingly, the
ability to produce IL-4 in response to polyclonal stimula-
tion with Con A was much higher in animals with 12 and
19 days, in comparison to 5-day-old (Fig. 3b).
3.4 pVAXhsp65 and BCG similarly prime neonate mice for 
a strong and mixed (Th1/Th2) anti-hsp65 response at the 
adult stage
Neonate mice (5-day-old) were primed with one dose of
pVAXhsp65 or BCG and boostered 4 weeks later with two
doses of pVAXhsp65, delivered two weeks apart. As can be
observed in Figure 4, both strategies triggered a significant
increase in the levels of IgG1 and IgG2a anti-hsp65 anti-
bodies, shown at Figure 4a and 4b, respectively. The prim-
ing effect of BCG and pVAXhsp65 seemed to be very
similar in intensity and quality because no statistical dif-
ferences were observed in specific IgG1 and IgG2a anti-
bodies when these two protocols were compared.
4. Discussion
This report provides evidence that pVAXhsp65, a genetic
vaccine constructed by insertion of the M. leprae hsp65
gene into a plasmid bacterial vector (pVAX), is transcribed
Tissue distribution of hsp65 messageF g re 1
Tissue distribution of hsp65 message. The presence of hsp65 message was evaluated in different tissue samples collected 
48 hours (a) and 7 days (b) after intramuscular injection of 50 ug of pVAXhsp65. Total RNA (10 ug) isolated from each tissue 
was treated with DNase and subjected to RT-PCR amplification with specific primers. β-actin was amplified as an RNA quality 
control. All RT-PCR products were analysed by agarose gel electrophoresis and visualized by ethidium bromide staining. Simi-
lar results were observed in two animals analysed for each period. No products were seen (hsp65 and β-actin) when total 
RNA was subjected to PCR amplification in the absence of a previous reverse transcription.
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by muscular cells of neonate mice. Additionally it shows
that even though it was weakly immunogenic when
entirely (3 doses) delivered during neonatal life, one dose
of this vaccine was able to strongly prime the immune sys-
tem of neonate mice to respond to a booster administered
later during the adult stage. We also observed that BCG
was able to prime neonate mice to respond to pVAXhsp65
later, in the adult life.
This investigation was initiated by evaluation of mRNA
for hsp65, by RT-PCR, in different tissues. Using only one
dose of 50 μg of pVAXhsp65 by intramuscular delivery, we
observed that hsp65 message was always present in the
muscle, i.e., at the inoculation site, even 7 days post-
immunization. This message was not found in secondary
lymphoid organs as spleen and lymph nodes as would be
expected from our previous results employing a very sim-
ilar vaccine in adult BALB/c mice [18]. The absence of
mRNA for hsp65 in secondary lymphoid organs could
explain, at least partially, the very low humoral immune
response induced by three doses of DNA delivered during
early life. However, this transcription limited to the inoc-
ulation site seemed sufficient to prime the animals for a
strong immune response induced later, at the adult life.
Absence of transcripts in the thymus was considered
important because the presence of mRNAhsp65 in the
thymus could be a concern, since the expression of anti-
gen in this tissue could induce tolerance by deletion of
hsp65-specific clones, altering the induction of specific
immunity after an immunization schedule [19].
Although we have shown before that a similar tuberculo-
sis vaccine did not integrate into the host cellular genome
[18], this kind of evaluation was considered mandatory in
very young mice (5-day-old). Due to their inherent high
cellular proliferative activity they could be more prone to
Immunomodulatory activity of pVAXhsp65 in young miceFigure 2
Immunomodulatory activity of pVAXhsp65 in young mice. Young mice received 3 pVAXhsp65 doses (50 μg/im route) 
delivered at 5, 12 and 19-day-old. Production of IFN-γ (a); IL-4 (b) and IL-5 (c) by splenic cells stimulated with ConA and serum 
levels of specific anti-hsp65 antibodies (d) were determined two weeks later. Results represent the geometric mean ± SEM of 
4 to 8 individually tested animals per group. *p < 0.05 in comparison to vector group.
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present plasmid integration into the genome. In addition,
this new vaccine construction (pVAXhsp65), that was not
previously tested and that could be acceptable for future
human studies, was adopted in this investigation. Also,
even though mRNA for hsp65 was found only in muscle
tissue, we could not exclude the presence of plasmid DNA
in other organs as spleen, liver, thymus and regional
lymph nodes. Therefore, Southern blot analysis was con-
ducted at different time points after immunization (48
and 72 hours and 7 days) in these tissues and also in mus-
cle samples. This analysis demonstrated that pVAXhsp65
did not integrate into the DNA at any time analyzed (data
not shown), confirming our previous observations in
adult BALB/c mice [18]. Although higher sensitive meth-
ods are necessary to definitively exclude a possible
genomic integration, these results are promising in the
context of new procedures for neonatal immunization
Comparative priming of neonate mice with pVAXhsp65 and BCG fo  sp cific anti-hsp65 an ibody productionFigure 4
Comparative priming of neonate mice with 
pVAXhsp65 and BCG for specific anti-hsp65 antibody 
production. Five-day-old mice received a priming dose of 
pVAXhsp65 or BCG and then two pVAXhsp65 doses at the 
adult phase; experimental groups were identified as DNA/
DNA and BCG/DNA respectively. A non-immunized group 
and a group immunized with 3 pVAXhsp65 doses delivered 
at 5, 12 and 19-day-old were identified as control and 
neonate, respectively. Two weeks after last dose, the serum 
levels of IgG1 (a) and IgG2a (b) anti-hsp65 antibodies were 
evaluated by ELISA. Results represent the geometric mean ± 
SEM of 6 – 8 individually tested animals per group. *p < 0.05 
in comparison to neonate group.
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Effect of mice's age on priming by pVAXhsp65 (a) 
and on IL-4 production (b). BALB/c mice were primed 
with pVAXhsp65 at distinct ages (5, 12, 19 and 30 days) and 
boostered with this vaccine 4 weeks later. Antibody serum 
levels were evaluated by ELISA 2 weeks after the booster. 
Results represent the geometric mean ± SEM of 4 to 8 ani-
mals individually tested per group. Ability to produce IL-4 
was tested in supernatants from splenic cells in mice with 5, 
12, 19 and 30-day-old stimulated in vitro with ConA. Results 
represent the geometric mean ± SEM of 5 animals individu-
ally tested, except for the 5 days old group that was tested 
by a pool of cells. # p < 0.05 in comparison to 19 and 30 
days; * p < 0.05 in comparison to the other groups.
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with DNA vaccines. These results are also in accordance
with previous reports that showed a negligible risk of
genomic integration after intramuscular inoculation of
different plasmid constructions [20-22].
Like many other vaccines designed for human use, it must
be considered that a new TB vaccine will be administered
to newborn children. With this in mind we evaluated
pVAXhsp65 immunogenicity for young mice. The immu-
nization schedule included 3 DNA doses delivered during
neonatal stage. The discrete immune response induced by
three consecutive DNA doses, all delivered before wean-
ing, could mean that the protocol (3 doses in 14 days) was
not highly immunogenic. The very short interval between
vaccine doses could be responsible for the observed low
immunogenicity. This possibility is clearly supported by
the work of Leitner et al.[23]. These authors demonstrated
that expanding the interval between the doses of a DNA
vaccine for malaria (circumsporozoite protein from Plas-
modium berghey) gave the strongest effect, increasing effi-
cacy and antibody boosting. However, a state of partial
tolerance could be also induced, due not only to the high
frequency of vaccination exposure but also to the fact that
neonate mice are much more prone to develop tolerance
depending on the conditions of antigen exposure [24]. To
more directly test the ability of this construction to induce
tolerance, we used a more appropriate and classical proto-
col that included one vaccine dose in neonates followed
by a second dose during adult life. In this case, high levels
of specific IgG2a and IgG1 were induced, demonstrating
that one pVAXhsp65 dose delivered during neonatal stage
was not tolerogenic. This absence of neonatal tolerance
was different from results obtained with a genetic vaccine
for malaria [25] but was in accordance with other investi-
gations that showed no tolerance induction by genetic
vaccines in neonates [26]. Interestingly, this priming effect
was strongly influenced by the age of the animal; the high-
est IgG2a levels, what suggest Th1 stimulation, were
observed in animals primed at 5-day-old. These findings
could be explained, at least partially, by the differential
production of IL-4 at these periods; highest IL-4 levels
coincided with the lowest IgG2a production during the
young stage.
Two main reasons make us to believe that regulatory T
cells (Treg cells) could be also involved in this low
immune response to pVAXhsp65 vaccination in neonates.
Even though they are not fully characterized, there are
enough experimental evidences showing that they can be
natural or induced and that they control immune
response to pathogens, tumors and even to self compo-
nents [27-29]. The first indication that Treg cells could be
important in the neonatal context came from experiments
showing that neonatal thymectomy lead to an increased
incidence of autoimmune diseases [30,31]. More recently,
the contribution of natural Treg cells during pregnancy,
maintaining maternal tolerance to the fetus, was
described [32]. A high proportion of CD4+CD25+ natural
Treg cells was also demonstrated in cord blood, being par-
ticularly higher in premature babies compared to full-
term babies [33]. Interestingly, these cells express Treg cell
markers as CTLA-4 and Foxp3 and also exert potent
immunosuppressive activity over proliferation and
cytokine production following stimulation with specific
antigen [33,34]. Besides this, the gene inserted in this
genetic construction codes for the heat shock protein
(hsp65) from Mycobacterium leprae. The contribution of
hsps (mainly hsp60/65) to control inflammation associ-
ated with autoimmune diseases has been abundantly
reported, including by researchers from our group [35-
37]. Hsp peptides and plasmid vaccines constructed with
hsp genes have been even tested in clinical trials due to
their ability to activate hsp-specific T reg cells [38]. In this
context, we could hypothesize that vaccination with
pVAXhsp65 during neonatal life is activating both, natural
and induced Treg cells, triggering therefore, an excessive
and early regulation of the immune response.
Even though the humoral specific immune response was
discrete, this immunization schedule was associated with
a strong immunomodulatory effect over the immune
response of vaccinated mice, characterized by higher IL-4
and IL-5 levels found in splenic cell cultures stimulated
with ConA. The origin of the elevated production of IL-4
and IL-5 was not investigated. However, based on the
characteristics of the neonate immune response, we could
imagine that a combination of different factors contrib-
uted to this immunomodulation. First, we believe that
this effect is related to the heat shock protein itself or its
encoding gene because only vaccinated animals (and not
the vector injected ones) presented this modulation. The
most simple explanation could be a strongly skewed Th2
response associated with a possible high amount of anti-
gen produced in a short period of time. Literature reports
on neonatal immunity support this possibility. Mouse
peripheral T cells in the first few weeks of life are a mixture
of fetal and adult derived cells and these CD4+ T cells of
fetal origin mount a Th2 skewed response in an antigen-
dose-dependent manner [39,40]. Interestingly, even
genetic vaccines that are claimed to be stronger Th1 induc-
ers in adult animals triggered Th1/Th2 mixed responses in
neonates [41,42]. This neonatal Th2 bias has been even
envisaged as a valuable tool for prophylaxis of autoim-
mune diseases [43]. It is important to highlight, however,
that this elevated production of Th2 cytokines could jeop-
ardize resistance to intracellular pathogens by, for exam-
ple, decreasing Th1 expression as has been discussed in
the context of new tuberculosis vaccines [44].
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As priming with pVAXhsp65 in 5-day-old mice triggered a
strong priming for IgG2a, we compared this with a BCG
priming delivered at the same period, i.e. 5-day-old. Both
groups were boostered with two pVAXhsp65 doses in the
adult phase. pVAXhsp65 and BCG similarly primed for a
strong humoral response, characterized by high levels of
both, IgG1 and IgG2a. These results suggest that both, the
genetic pVAXhsp65 vaccine and BCG were able to prime
neonate mice for a strong immune response to
pVAXhsp65 boosters delivered later, in the adult life. Even
though these strategies appear promising in the search for
a new TB vaccine, the mixed Th1/Th2 response will not,
probably, be able to control TB infection. This assumption
is based on the extensive literature that considers these
aspects [45-47].
5. Conclusion
Together, the observed results suggest that this genetic vac-
cine is safe and very powerful to prime neonate mice
immune system. This could be further explored with pro-
tocols designed to shape the induced immunity to a pro-
tective kind of response against TB. An attractive
possibility is to reinforce Th1 polarization during neona-
tal period by addition of GM-CSF and IL-12 plasmids or
even CpG motifs.
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